https://crstoday.com/news/sightglass-vision-announces-andrew-sedgwick-as-ceo-names-additional-executive-leaders/2480716/daily0.7https://crstoday.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/daily0.7https://crstoday.com/news/zenni-and-prevent-blindness-partner-to-launch-the-zenni-scholarship-to-advance-childrens-vision/2480713/daily0.7https://crstoday.com/news/panoptix-trifocal-iol-surpasses-one-million-implants-worldwide/2480711/daily0.7https://crstoday.com/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia/2480710/daily0.7https://crstoday.com/news/innovega-announces-public-funding-campaign-with-startenginecom/2480709/daily0.7https://crstoday.com/news/horizon-therapeutics-and-iapb-partner-to-advocate-for-better-eye-health/2480708/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer/2480707/daily0.7https://crstoday.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/daily0.7https://crstoday.com/news/nominations-now-being-accepted-for-nora-awards/2480704/daily0.7https://crstoday.com/news/oyster-point-pharma-announces-retirement-of-william-j-link-from-board-of-directors/2483662/daily0.7https://crstoday.com/news/visus-therapeutics-announces-appointment-of-julia-williams-as-vice-president-of-clinical-and-medical-affairs-and-expansion-of-irvine-co-headquarters/2480703/daily0.7https://crstoday.com/news/bryan-wolynski-named-chief-technology-officer-at-lighthouse-guild/2480702/daily0.7https://crstoday.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/daily0.7https://crstoday.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/daily0.7https://crstoday.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/daily0.7https://crstoday.com/news/uarizona-engineer-leads-1m-project-to-fight-vision-loss/2480692/daily0.7https://crstoday.com/news/eyenuk-joins-the-population-health-alliance-paving-way-for-autonomous-ai-to-improve-diabetes-complications/2480690/daily0.7https://crstoday.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/daily0.7https://crstoday.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/daily0.7https://crstoday.com/news/dorc-launches-eva-nexus/2480687/daily0.7https://crstoday.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/daily0.7https://crstoday.com/news/lumibird-medical-launches-new-website-dedicated-to-laser-therapies-for-each-glaucoma-stage/2480684/daily0.7https://crstoday.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/daily0.7https://crstoday.com/news/okogen-names-ophthalmology-industry-veteran-joshua-moriarty-as-new-chief-executive-officer/2480682/daily0.7https://crstoday.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/daily0.7https://crstoday.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/daily0.7https://crstoday.com/news/heru-appoints-former-amazon-executive-brandon-barber-as-chief-marketing-officer/2480679/daily0.7https://crstoday.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/daily0.7https://crstoday.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/daily0.7https://crstoday.com/news/lumithera-completes-acquisition-of-diopsys/2480675/daily0.7https://crstoday.com/news/santen-establishes-its-first-external-research-laboratory-in-europe-at-the-ucl-institute-of-ophthalmology-in-london/2480674/daily0.7https://crstoday.com/news/nicoxs-partner-fera-pharmaceuticals-obtains-orphan-drug-designation-from-the-us-fda-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/2480673/daily0.7https://crstoday.com/news/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus/2480672/daily0.7https://crstoday.com/news/lensar-announces-us-food-and-drug-administration-acceptance-of-510k-submission-for-ally/2480671/daily0.7https://crstoday.com/news/new-world-medical-announces-launch-details-for-streamline/2483661/daily0.7https://crstoday.com/news/nicoxs-partner-ocumension-obtains-positive-phase-3-clinical-trial-results-for-zerviate-in-china/2480670/daily0.7https://crstoday.com/news/lighthouse-guild-to-launch-new-technology-center-in-manhattan/2480669/daily0.7https://crstoday.com/news/essilorluxottica-closes-acquisition-of-walman-optical/2480668/daily0.7https://crstoday.com/news/veo-ophthalmics-teams-up-with-aniridia-foundation-international-to-promote-rare-disease-day/2480667/daily0.7https://crstoday.com/news/prevent-blindness-to-hold-17th-annual-eyes-on-capitol-hill-advocacy-event/2480666/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-appoints-gary-sternberg-md-mba-as-chief-medical-officer/2480665/daily0.7https://crstoday.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/daily0.7https://crstoday.com/news/allergan-to-present-data-from-durysta-and-xen-gel-stent-at-the-2022-american-glaucoma-society-ags-annual-meeting/2480663/daily0.7https://crstoday.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/daily0.7https://crstoday.com/news/nicox-announces-vyzulta-now-commercialized-in-7-territories-and-approved-in-further-9-countries/2480660/daily0.7https://crstoday.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/daily0.7https://crstoday.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/daily0.7https://crstoday.com/news/nicox-granted-patent-for-ncx-470-in-china-extending-coverage-to-2039/2480655/daily0.7https://crstoday.com/news/alpine-and-shamir-extend-strategic-partnership-into-esports-world/2480654/daily0.7https://crstoday.com/news/santen-launches-eyecare-education-learning-portal-for-ophthalmologists-in-europe/2480651/daily0.7https://crstoday.com/news/elios-reports-8-year-results-of-its-excimer-laser-trabeculostomy-procedure-combined-with-cataract-surgery/2480650/daily0.7https://crstoday.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/daily0.7https://crstoday.com/news/new-post-marketing-safety-analysis-shows-rate-of-hearing-related-events-associated-with-tepezza-comparable-with-clinical-trial-observations/2480647/daily0.7https://crstoday.com/news/essilorluxottica-introduces-new-leonardo-myopia-certification-program/2480646/daily0.7https://crstoday.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/daily0.7https://crstoday.com/news/sifi-provides-regulatory-updates-for-akantior-polihexanide-08-mgml-in-europe-and-the-united-states/2480643/daily0.7https://crstoday.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/daily0.7https://crstoday.com/news/professor-tero-kivela-receives-the-ico-ophthalmic-pathology-award/2483660/daily0.7https://crstoday.com/news/euclid-systems-expands-us-commercial-team/2480634/daily0.7https://crstoday.com/news/proqr-does-not-meet-primary-or-secondary-endpoints-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10/2480633/daily0.7https://crstoday.com/news/waldo-announces-the-acquisition-of-placid0/2480632/daily0.7https://crstoday.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/daily0.7https://crstoday.com/news/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2480630/daily0.7https://crstoday.com/news/bausch-health-files-for-solta-ipo/2480629/daily0.7https://crstoday.com/news/glaukos-announces-executive-leadership-changes/2480628/daily0.7https://crstoday.com/news/study-shows-significant-impact-of-novel-omega-3-and-omega-6-supplement-for-people-with-severe-dry-eye-disease/2480627/daily0.7https://crstoday.com/news/global-eye-health-body-unites-with-novartis-to-strengthen-eye-health-in-africa/2480626/daily0.7https://crstoday.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/daily0.7https://crstoday.com/news/lumenis-partners-with-mandy-moore-partners-to-raise-awareness-of-dry-eye-disease-and-optilight-treatment/2480624/daily0.7https://crstoday.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/daily0.7https://crstoday.com/news/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission/2480621/daily0.7https://crstoday.com/news/nicox-positive-fda-meeting-shows-clear-path-for-ncx-4251-in-dry-eye/2480620/daily0.7https://crstoday.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/daily0.7https://crstoday.com/news/tearclear-announces-initiation-of-tc-002-latanoprost-ophthalmic-solution-phase-3-trial/2480617/daily0.7https://crstoday.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/daily0.7https://crstoday.com/news/i-med-pharma-usa-partners-with-dryeye-rescue-to-distribute-its-dry-eye-product-portfolio-in-the-united-states/2480614/daily0.7https://crstoday.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/daily0.7https://crstoday.com/news/fda-approves-first-generic-of-restasis/2480612/daily0.7https://crstoday.com/news/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/2480611/daily0.7https://crstoday.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/daily0.7https://crstoday.com/news/globaldata-glaucoma-market-to-grow-to-35-billion-by-2030-driven-by-launch-of-new-pipeline-products/2480609/daily0.7https://crstoday.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/daily0.7https://crstoday.com/news/heidelberg-engineering-supports-glaucomamyopia-oct-phenotyping-consortium/2480607/daily0.7https://crstoday.com/news/thea-to-acquire-branded-ophthalmic-products-from-akorn/2480606/daily0.7https://crstoday.com/news/hubble-lenses-fined-millions-after-settling-charges-it-violated-the-contact-lens-rule-and-ftc-act-to-boost-sales/2480604/daily0.7https://crstoday.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/daily0.7https://crstoday.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/daily0.7https://crstoday.com/news/first-uk-patient-receives-bionic-eye-implant-to-help-partially-restore-vision/2480601/daily0.7https://crstoday.com/news/ted-davis-to-succeed-amy-tseng-as-president-and-ceo-of-tissuetech/2483659/daily0.7https://crstoday.com/news/nanodropper-and-lumata-health-launch-partnership-aimed-at-improving-patient-care/2480600/daily0.7https://crstoday.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-demonstrating-the-clinical-benefit-of-the-prima-system-in-dry-amd-patients/2480597/daily0.7https://crstoday.com/news/mitotech-to-host-key-opinion-leader-webinar-on-visomitin-a-potential-treatment-for-dry-eye-disease/2480596/daily0.7https://crstoday.com/news/haag-streit-realigns-its-organization-to-focus-on-solutions-in-eye-care/2480595/daily0.7https://crstoday.com/news/refractive-surgery-council-reports-32-ytd-increase-in-laser-vision-correction-procedure-volume-over-2020/2480591/daily0.7https://crstoday.com/news/nih-study-classifies-vision-loss-and-retinal-changes-in-stargardt-disease/2480590/daily0.7https://crstoday.com/news/researchers-define-keys-to-recognizing-ocular-rosacea/2480589/daily0.7https://crstoday.com/news/maximeyescom-by-first-insight-partners-with-edgepro-by-gpn-technologies/2480588/daily0.7https://crstoday.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/daily0.7https://crstoday.com/news/2022-president-robert-e-wiggins-jr-md-mph-takes-the-academys-reins/2480585/daily0.7https://crstoday.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/daily0.7https://crstoday.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/daily0.7https://crstoday.com/news/foundation-fighting-blindness-promotes-jason-menzo-to-president-and-chief-operating-officer/2480580/daily0.7https://crstoday.com/news/euclid-systems-launches-myeuclid-customer-portal/2480579/daily0.7https://crstoday.com/news/several-changes-made-in-leadership-of-allergan-eye-care/2480578/daily0.7https://crstoday.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/daily0.7https://crstoday.com/news/avellino-enters-into-distribution-agreement-with-keeler-to-sell-genetic-eye-test-avagen/2480576/daily0.7https://crstoday.com/news/allotex-announces-3-year-results-of-allogeneic-inlays-for-the-treatment-of-hyperopia-and-presbyopia/2480575/daily0.7https://crstoday.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/daily0.7https://crstoday.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/daily0.7https://crstoday.com/news/visionweb-and-neurolens-collaborate-to-increase-prism-specificity/2480572/daily0.7https://crstoday.com/news/bausch-lomb-corporation-files-registration-statement-and-preliminary-prospectus-for-proposed-initial-public-offering/2480570/daily0.7https://crstoday.com/news/envision-conference-announces-2022-in-person-date-calls-for-submissions/2480569/daily0.7https://crstoday.com/news/market-scope-global-refractive-market-rebounds-strongly-after-covid-19/2480568/daily0.7https://crstoday.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/daily0.7https://crstoday.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/daily0.7https://crstoday.com/news/unitedhealthcare-enhances-eye-care-program-by-helping-reduce-peoples-exposure-to-blue-light/2480563/daily0.7https://crstoday.com/news/envision-opens-first-of-its-kind-national-gallery-exhibiting-art-for-and-by-blind-or-visually-impaired-artists-and-audiences/2480562/daily0.7https://crstoday.com/news/reichert-technologies-celebrates-100-years-of-phoroptor/2480561/daily0.7https://crstoday.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/daily0.7https://crstoday.com/news/coopervision-facilitates-special-olympics-opening-eyes-ce-series/2480559/daily0.7https://crstoday.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/daily0.7https://crstoday.com/news/aldeyra-therapeutics-announces-positive-topline-data-from-phase-2-dry-eye-chamber-clinical-trial-of-reproxalap-for-dry-eye-disease/2480557/daily0.7https://crstoday.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/daily0.7https://crstoday.com/news/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-clinical-achievements/2480554/daily0.7https://crstoday.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/daily0.7https://crstoday.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/daily0.7https://crstoday.com/news/oxurion-provides-update-on-clinical-pipeline-progress/2480551/daily0.7https://crstoday.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/daily0.7https://crstoday.com/news/rayner-expands-rayone-portfolio-with-companys-first-blue-light-filtering-iol/2480548/daily0.7https://crstoday.com/news/prevent-blindness-issues-call-for-nominations-for-2022-national-awards/2480547/daily0.7https://crstoday.com/news/ocuphire-announces-enrollment-completion-of-phase-3-nyxol-trial-and-enrollment-initiation-of-nyxol-pediatric-trial/2480546/daily0.7https://crstoday.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/daily0.7https://crstoday.com/news/tarsus-appoints-elizabeth-yeu-md-to-its-board-of-directors/2483658/daily0.7https://crstoday.com/news/eyed-lands-51m-to-take-glaucoma-implant-into-the-clinic/2480544/daily0.7https://crstoday.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses/2480543/daily0.7https://crstoday.com/news/new-survey-from-bausch-lomb-and-glaucoma-research-foundation-reveals-emotional-and-social-impact-of-hyperemia-on-glaucoma-patients/2480542/daily0.7https://crstoday.com/news/the-latest-in-comanagement-best-practices/2480541/daily0.7https://crstoday.com/news/retina-consultants-of-america-partners-with-retina-consultants-of-charleston/2480539/daily0.7https://crstoday.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/daily0.7https://crstoday.com/news/retina-consultants-of-america-announces-addition-of-brown-retina-institute/2480537/daily0.7https://crstoday.com/news/omeros-completes-sale-of-omidria-franchise-to-rayner-surgical/2480536/daily0.7https://crstoday.com/news/us-authorizes-pfizers-covid-19-pill-paxlovid/2480535/daily0.7https://crstoday.com/news/global-data-primary-open-angle-glaucoma-total-prevalent-cases-to-reach-884-million-by-2030/2480534/daily0.7https://crstoday.com/news/rayner-appoints-esteemed-ophthalmic-leaders-as-strategic-advisors-and-is-awarded-ide-for-trifocal-iols/2480533/daily0.7https://crstoday.com/news/biden-announces-free-home-covid-testing-emergency-hospital-support-to-head-off-winter-omicron-surge/2483657/daily0.7https://crstoday.com/news/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd/2480531/daily0.7https://crstoday.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/daily0.7https://crstoday.com/news/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-12a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2480529/daily0.7https://crstoday.com/news/aldeyra-therapeutics-to-modify-phase-3-tranquility-trial-in-dry-eye-disease-after-missing-primary-endpoint/2480528/daily0.7https://crstoday.com/news/belkin-vision-to-receive-eur175m-grant-from-european-innovation-council/2483656/daily0.7https://crstoday.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/daily0.7https://crstoday.com/news/us-eye-expands-into-now-5-states-50-clinics-and-5-ascs-100-providers-and-1000-team-members/2480526/daily0.7https://crstoday.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/daily0.7https://crstoday.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/daily0.7https://crstoday.com/news/michael-bolle-appointed-designated-chairman-of-carl-zeiss-ag-supervisory-board/2483655/daily0.7https://crstoday.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/daily0.7https://crstoday.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/daily0.7https://crstoday.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/daily0.7https://crstoday.com/news/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer/2480519/daily0.7https://crstoday.com/news/jeff-sieve-appointed-ceo-of-haag-streit-usa/2480518/daily0.7https://crstoday.com/news/pioneering-ophthalmologist-william-j-lahners-passes-away/2480517/daily0.7https://crstoday.com/news/ntc-and-i-med-pharma-partner-to-bring-ha-based-dry-eye-ointment-to-the-united-states-market/2480516/daily0.7https://crstoday.com/news/onesight-provided-25000-people-access-to-vision-care-this-fall/2483654/daily0.7https://crstoday.com/news/ivantis-announces-first-patient-enrolled-in-pivotal-clinical-trial-evaluating-the-hydrus-microstent-in-standalone-migs-for-mild-to-moderate-glaucoma/2480515/daily0.7https://crstoday.com/news/aramis-biosciences-launches-to-address-unmet-needs-in-ocular-immunology/2480514/daily0.7https://crstoday.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/daily0.7https://crstoday.com/news/world-council-of-optometry-to-host-global-myopia-management-virtual-event/2480511/daily0.7https://crstoday.com/news/nih-study-traces-molecular-link-from-gene-to-late-onset-retinal-degeneration/2480510/daily0.7https://crstoday.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/daily0.7https://crstoday.com/news/retina-consultants-of-america-announces-addition-of-mississippi-retina-associates/2480508/daily0.7https://crstoday.com/news/firmaments-midwest-vision-partners-acquires-discover-vision-centers-expansion-into-kansas-city-market/2480507/daily0.7https://crstoday.com/news/tearlab-announces-adam-szaronos-as-president-and-ceo-and-jim-mazzo-as-executive-chairman-of-the-board/2480506/daily0.7https://crstoday.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/daily0.7https://crstoday.com/news/recently-approved-presbyopia-eye-drop-vuity-now-available-in-pharmacies/2480503/daily0.7https://crstoday.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/daily0.7https://crstoday.com/news/ocuphire-expands-medical-advisory-board-to-support-advancement-of-late-stage-ophthalmic-assets-nyxol-and-apx3330/2480500/daily0.7https://crstoday.com/news/imprimisrx-to-assume-full-responsibility-for-us-sales-and-marketing-activities-for-dexycu/2480499/daily0.7https://crstoday.com/news/acufocus-receives-approvable-letter-from-fda-for-ic-8-small-aperture-iol/2480498/daily0.7https://crstoday.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/daily0.7https://crstoday.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/daily0.7https://crstoday.com/news/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressa-and-rocklatan-in-europe-and-several-other-regions/2480495/daily0.7https://crstoday.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/daily0.7https://crstoday.com/news/envision-acquires-national-virtual-program-to-help-students-who-are-blind-or-visually-impaired/2480492/daily0.7https://crstoday.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/daily0.7https://crstoday.com/news/cofi-announces-300-eye-care-practices-now-use-cofis-compliant-co-management-payments-tool-for-ophthalmology-procedures/2480490/daily0.7https://crstoday.com/news/new-technology-greater-patient-awareness-will-help-drive-gains-in-premium-cataract-surgery/2480489/daily0.7https://crstoday.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/daily0.7https://crstoday.com/news/ophthalmic-sciences-unveils-ai-contactless-device-for-measuring-iop/2480487/daily0.7https://crstoday.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/daily0.7https://crstoday.com/news/implandata-wins-medica-innovation-world-cup-1st-place-of-300-digital-health-ventures/2480485/daily0.7https://crstoday.com/news/moderna-regeneron-warn-about-the-effectiveness-of-covid-19-drugs-vaccines-against-the-omicron-variant/2480484/daily0.7https://crstoday.com/news/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board-of-directors/2480483/daily0.7https://crstoday.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/daily0.7https://crstoday.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/daily0.7https://crstoday.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/daily0.7https://crstoday.com/news/vsy-biotechnology-gmbh-discovers-how-to-connect-the-golden-ratio-concept-to-its-new-intraocular-lens-technology/2480479/daily0.7https://crstoday.com/news/kubota-vision-announces-publication-in-scientific-reports-of-study-data-for-wearable-myopia-control-device/2480478/daily0.7https://crstoday.com/news/variant-receives-european-orphan-drug-designation-for-its-gene-therapy-product-candidate-var002-for-the-treatment-of-both-leber-congenital-amaurosis-and-cone-rod-dystrophy/2483653/daily0.7https://crstoday.com/news/pixium-vision-to-present-at-btigs-ophthalmology-day/2483652/daily0.7https://crstoday.com/news/coopercompanies-announces-executive-management-changes/2480477/daily0.7https://crstoday.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/daily0.7https://crstoday.com/news/iolcon-is-mapping-out-the-road-for-reliable-iol-calculation/2480474/daily0.7https://crstoday.com/news/hilco-vision-acquires-belgium-and-netherlands-based-simovision-bv/2480473/daily0.7https://crstoday.com/news/coopervision-opens-applications-for-its-2022-best-practices-scholarship-program/2483651/daily0.7https://crstoday.com/news/amneal-receives-approval-for-difluprednate-ophthalmic-emulsion/2483650/daily0.7https://crstoday.com/news/evoq-technologies-llc-announces-launch-of-first-smartphone-based-product-for-retinal-health-testing/2480471/daily0.7https://crstoday.com/news/herus-wearable-diagnostic-health-and-wellness-platform-honored-with-prestigious-ces-innovation-award-by-the-consumer-technology-association-cta/2483649/daily0.7https://crstoday.com/news/aao-new-research-shows-virtual-school-can-harm-childrens-vision/2480470/daily0.7https://crstoday.com/news/ocutrx-technologies-receives-three-patents-on-near-eye-pupil-forming-catadioptric-optical-engine/2480469/daily0.7https://crstoday.com/news/zeiss-celebrates-175-years-in-optics/2480468/daily0.7https://crstoday.com/news/updated-cataract-ppp-raises-questions-about-same-day-bilateral-cataract-surgery-and-office-based-cataract-surgery/2480467/daily0.7https://crstoday.com/news/cant-get-relief-from-dry-eye-new-research-may-explain-why/2480466/daily0.7https://crstoday.com/news/euclid-systems-names-key-leadership-hires-and-announces-major-facility-expansion/2480465/daily0.7https://crstoday.com/news/the-national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-convenes-new-childrens-vision-equity-alliance/2480464/daily0.7https://crstoday.com/news/microinvasive-glaucoma-surgery-with-the-omni-surgical-system-is-associated-with-diminished-diurnal-iop-fluctuations/2480463/daily0.7https://crstoday.com/news/retina-consultants-of-america-continues-growth-by-adding-pacific-northwest-retina/2480461/daily0.7https://crstoday.com/news/istar-medical-receives-european-market-approval-for-glaucoma-implant-miniject/2480460/daily0.7https://crstoday.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/daily0.7https://crstoday.com/news/edenlux-launches-campaign-for-otus-personal-eye-trainer/2480458/daily0.7https://crstoday.com/news/santen-to-introduce-first-plant-derived-eye-drop-bottle-in-emea-to-help-reduce-reliance-on-fossil-fuel-based-plastic/2480457/daily0.7https://crstoday.com/news/avellino-appoints-jon-robson-as-ceo-and-member-of-the-board-of-directors/2480456/daily0.7https://crstoday.com/news/clearside-biomedical-features-fda-approved-xipere-in-multiple-presentations-at-aao-and-american-uveitis-society-meetings/2480454/daily0.7https://crstoday.com/news/revelstoke-completes-sale-of-cei-vision-partners-to-eyecare-partners/2480453/daily0.7https://crstoday.com/news/eyenuk-announces-publication-of-strong-eyeart-pivotal-clinical-trial-results-in-jama-network-open/2480451/daily0.7https://crstoday.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/daily0.7https://crstoday.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/daily0.7https://crstoday.com/news/bausch-lomb-reports-more-than-41-million-units-of-contact-lens-eye-and-lens-care-materials-recycled/2480448/daily0.7https://crstoday.com/news/cxl-ophthalmics-announces-positive-results-of-phase-2-clinical-trial-in-epi-on-cross-linking-for-keratoconus/2480447/daily0.7https://crstoday.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/daily0.7https://crstoday.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/daily0.7https://crstoday.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/daily0.7https://crstoday.com/news/aao-top-four-issues-threatening-ophthalmologys-financial-stability/2480440/daily0.7https://crstoday.com/news/new-real-world-data-show-high-rate-of-patient-adherence-to-tepezza-for-thyroid-eye-disease-ted/2480439/daily0.7https://crstoday.com/news/vsy-biotechnology-launches-acrivaud-trinova-pro-c-pupil-adaptive-trifocal-iol/2480438/daily0.7https://crstoday.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/daily0.7https://crstoday.com/news/modmed-surpasses-100-million-patient-encounters-in-eye-care/2483648/daily0.7https://crstoday.com/news/cord-llc-completes-one-year-follow-up-on-subjects-from-the-model-sc9-intraocular-lens-fda-clinical-trial/2480435/daily0.7https://crstoday.com/news/new-analysis-reveals-impact-of-the-covid-19-pandemic-on-the-ophthalmic-community/2480434/daily0.7https://crstoday.com/news/johnson-johnson-to-spin-out-consumer-health-business-in-new-publicly-traded-company/2483647/daily0.7https://crstoday.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/daily0.7https://crstoday.com/news/ziemer-usa-announces-partnership-with-corneagen/2480429/daily0.7https://crstoday.com/news/the-eye-institute-of-west-florida-joins-eyecare-partners/2483646/daily0.7https://crstoday.com/news/fda-authorizes-sight-sciences-precision-trial-of-canal-viscodilation-in-combination-with-cataract-surgery-in-adults-with-poag/2480428/daily0.7https://crstoday.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/daily0.7https://crstoday.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/daily0.7https://crstoday.com/news/in-office-mgd-procedure-market-is-largely-untapped-survey-shows/2480424/daily0.7https://crstoday.com/news/jim-mazzo-joining-board-of-directors-at-tearlab/2480423/daily0.7https://crstoday.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/daily0.7https://crstoday.com/news/study-shows-contact-lenses-advantages-with-mask-wear/2480420/daily0.7https://crstoday.com/news/regenerons-antibody-cocktail-offers-long-term-protection-against-covid-19/2480418/daily0.7https://crstoday.com/news/oyster-point-pharma-to-present-data-at-the-american-academy-of-ophthalmology-annual-meeting-2021/2480417/daily0.7https://crstoday.com/news/ocuterra-raises-35-million-series-b-financing/2480416/daily0.7https://crstoday.com/news/allergan-to-present-data-from-its-eye-care-portfolio-at-the-aao-annual-meeting-including-new-vuity-analysis/2480415/daily0.7https://crstoday.com/news/alcon-unveils-latest-evolution-of-cataract-integration-and-connectivity-at-aao-2021/2480414/daily0.7https://crstoday.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/daily0.7https://crstoday.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/daily0.7https://crstoday.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/daily0.7https://crstoday.com/news/retina-and-glaucoma-experts-to-present-best-practices-using-iridex-technologies-during-consensus-panel-and-aao/2480409/daily0.7https://crstoday.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/daily0.7https://crstoday.com/news/refractive-surgery-council-reports-48-ytd-increase-in-laser-vision-correction-procedure-volume-over-2020/2480407/daily0.7https://crstoday.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/daily0.7https://crstoday.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/daily0.7https://crstoday.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/daily0.7https://crstoday.com/news/oyster-point-pharma-announces-patient-savings-program-where-eligible-patients-can-pay-as-little-as-0-for-tyrvaya-nasal-spray/2480401/daily0.7https://crstoday.com/news/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia/2480400/daily0.7https://crstoday.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/daily0.7https://crstoday.com/news/prism-vision-group-acquires-three-new-practices/2480398/daily0.7https://crstoday.com/news/vsp-vision-care-acquires-icare-health-solutions/2480397/daily0.7https://crstoday.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/daily0.7https://crstoday.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/daily0.7https://crstoday.com/news/avellino-donates-25000-to-national-keratoconus-foundation-to-support-world-keratoconus-day-and-disease-education/2480393/daily0.7https://crstoday.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/daily0.7https://crstoday.com/news/aao-during-medicare-open-enrollment-time-beware-of-plan-restrictions-that-limit-access-to-sight-saving-care/2480389/daily0.7https://crstoday.com/news/bausch-lomb-to-present-scientific-data-and-analyses-at-upcoming-eye-care-meetings/2480388/daily0.7https://crstoday.com/news/eyepoint-pharmaceuticals-appoints-jay-s-duker-md-as-chief-operating-officer/2480387/daily0.7https://crstoday.com/news/fda-clears-emergency-use-of-comirnaty-in-children-aged-5-to-11/2480386/daily0.7https://crstoday.com/news/fda-approves-allergans-vuity-the-first-and-only-eye-drop-to-treat-presbyopia/2480385/daily0.7https://crstoday.com/news/ocular-therapeutix-to-present-data-at-the-american-academy-of-ophthalmology-aao-2021-virtual-annual-meeting/2480384/daily0.7https://crstoday.com/news/eyecare-partners-acquires-cei-vision-partners/2480383/daily0.7https://crstoday.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/daily0.7https://crstoday.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/daily0.7https://crstoday.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/daily0.7https://crstoday.com/news/icare-usa-to-commercialize-oculo-software-solution-platform-that-connects-doctors-with-each-other-and-their-patients/2480379/daily0.7https://crstoday.com/news/ai-powered-glaucoma-screening-test-delivers-rapid-results/2480378/daily0.7https://crstoday.com/news/allergan-to-present-new-data-on-investigational-agn-190584-for-the-treatment-of-presbyopia/2480377/daily0.7https://crstoday.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/daily0.7https://crstoday.com/news/bausch-lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-for-the-treatment-of-macular-edema-associated-with-uveitis/2480374/daily0.7https://crstoday.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/daily0.7https://crstoday.com/news/horizon-therapeutics-newly-published-data-continue-to-support-long-term-efficacy-of-tepezza-for-thyroid-eye-disease-ted/2480371/daily0.7https://crstoday.com/news/new-essilor-vision-care-center-hosts-first-virtual-global-varilux-summit-focused-on-presbyopia/2480370/daily0.7https://crstoday.com/news/luminopia-announces-fda-approval-of-digital-therapeutic-to-improve-vision-in-children-with-lazy-eye/2480369/daily0.7https://crstoday.com/news/retina-consultants-of-america-adds-colorado-retina-associates/2480368/daily0.7https://crstoday.com/news/sight-sciences-announces-tearcare-clinical-data-published-in-cornea/2480366/daily0.7https://crstoday.com/news/hanita-lenses-launches-new-website-as-part-of-40th-anniversary/2480365/daily0.7https://crstoday.com/news/prevent-blindness-senate-fy2022-appropriations-bill-doubles-funding-for-the-cdcs-vision-and-eye-health-program/2480364/daily0.7https://crstoday.com/news/optimo-medical-raises-additional-chf-18m-to-expand-eye-surgery-planning-portfolio/2480363/daily0.7https://crstoday.com/news/sifi-announces-positive-topline-results-of-the-pivotal-phase-3-study-of-polihexanide-for-the-treatment-of-acanthamoeba-keratitis/2480362/daily0.7https://crstoday.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/daily0.7https://crstoday.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/daily0.7